Impact of the total lesion glycolysis (TLG) in predicting response of follicular lymphoma to rituximab.

The article discusses the impact of total lesion glycolysis (TLG) in predicting the response of follicular lymphoma (FL) to rituximab. FL is a common type of non-Hodgkin lymphoma characterized by the (14;18) translocation. The study evaluates whether early rituximab monotherapy could delay chemotherapy in FL patients with low tumor burden. Results suggest that patients with FL should be evaluated using 18F-FDG PET scan and stratified based on TMTV and TLG thresholds to guide treatment decisions. [Extracted from the article]